Are you Dr. Xu?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 16 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
7301 College Blvd
Ste. 110
Overland Park, KS 66210Phone+1 913-341-6297Fax+1 913-341-6299
Summary
- Dr. Xiao Xu, MD is a board certified pathologist in Overland Park, Kansas. She is currently licensed to practice medicine in Kansas, Arizona, and Texas. She is affiliated with Overland Park Regional Medical Center.
Education & Training
- Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Pathology-Anatomic and Clinical, 1995 - 1998
- Shanghai Medical UniversityClass of 1987
Certifications & Licensure
- AZ State Medical License 2019 - 2026
- CA State Medical License 2017 - 2024
- TX State Medical License 2019 - 2021
- KS State Medical License 2009 - 2020
- MO State Medical License 2010 - 2020
- American Board of Pathology Anatomic Pathology & Clinical Pathology
Publications & Presentations
PubMed
- 6 citationsEndometrial Sampling for Preoperative Diagnosis of Uterine Leiomyosarcoma.Rosanne M. Kho, Vrunda B. Desai, Peter E. Schwartz, Jason D. Wright, Cary P. Gross
Journal of Minimally Invasive Gynecology. 2021-07-13 - 4 citationsHospital variation in responses to safety warnings about power morcellation in hysterectomy.Xiao Xu, Vrunda B. Desai, Jason D. Wright, Haiqun Lin, Peter E. Schwartz
American Journal of Obstetrics and Gynecology. 2021-06-01 - 28 citationsPrevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomyVrunda B. Desai, Jason D. Wright, Cary P. Gross, Haiqun Lin, Francis P. Boscoe
American Journal of Obstetrics and Gynecology. 2019-07-01
Press Mentions
- Effects of ATP9A on Extracellular Vesicle Release and Exosomal Lipid CompositionOctober 29th, 2020
- Severity of Early Allograft Dysfunction Following Donation After Circulatory Death Liver Transplantation: A Multicentre StudyOctober 14th, 2019
- ACEA Biosciences Announces Successful Completion of Phase I Clinical Study of Novel Autoimmune Disease DrugJune 14th, 2017